



December 2008

Volume 13 · Numbers 23/24

pp. 1013–1110



Cover Story

The featured review in this issue of *Drug Discovery Today*, by Georg Pilz, Peter Wipfler, Gunther Ladurner and Jörg Kraus outlines the developments in treatments for multiple sclerosis (MS) since the introduction of the first evidence-based therapeutics (glatiramer acetate and interferon β) in the mid 1990s. This heralded change in how MS was viewed, in that it was no longer the focus of just patients and physicians and scientists and Pharmaceutical companies began to see the condition as a tractable problem. The authors review the current state-of-the-art and discuss potential future treatment options for MS.

Cover image: © PHOTOTAKE Inc. / Alamy

DRUG DISCOVERY TODAY

REVIEWS

KEYNOTE

1013 Modern multiple sclerosis treatment – what is approved, what is on the horizon

Georg Pilz, Peter Wipfler, Gunther Ladurner and Jörg Kraus

1026 CB1 receptor antagonism: biological basis for metabolic effects

Vincenzo Di Marzo

GENE TO SCREEN

1042 Proteomics studies reveal important information on small molecule therapeutics: a case study on plasma proteins

Lello Zolla

INFORMATICS

1052 The impact of accelerator processors for high-throughput molecular modeling and simulation

G. Giupponi, M.J. Harvey and G. De Fabritiis

POST SCREEN

1059 Physiological relevance of GPCR oligomerization and its impact on drug discovery

Rosemarie Panetta and Michael T. Greenwood

1067 Peptide-assisted traffic engineering for nonviral gene therapy

Esther Vázquez, Neus Ferrer-Miralles and Antonio Villaverde

1075 Recent developments in microwave-assisted protein chemistries – can this be integrated into the drug discovery and validation process?

Wendy N. Sandoval, Victoria C. Pham and Jennie R. Lill

1082 Neuroprotection in traumatic brain injury

K.K. Jain

1090 New anti-tuberculosis drugs in clinical trials with novel mechanisms of action

Emma C. Rivers and Ricardo L. Mancera

1099 The targeted delivery of cancer drugs across the blood–brain barrier: chemical modifications of drugs or drug-nanoparticles?

Lucienne Juillerat-Jeanneret